| Autor: |
Khairy, Rasha M. M., Esmail, Mona Abdel Monem, Hammad, Safaa Said, Sayed, Mohamed, Ahmed, Hazem A., Abdelrahim, Soha S. |
| Předmět: |
|
| Zdroj: |
Microbes & Infectious Diseases; Spring2021, Vol. 2 Issue 2, p271-279, 9p |
| Abstrakt: |
Background: The main line of treatment of hepatitis C in Egypt is direct acting antiviral drugs (DAAs). Objectives: The current study aimed to explore the effect of IL28B genetic polymorphism on hepatitis C virus (HCV) infection progression and response to the new treatment in difficulty to treat individuals with HCV genotype 4. Methods: Blood samples were collected from 50 healthy individuals as a control and 150 HCV- patients receiving sofosbuvir/daclatasvir (SOF/DCV) with ribavirin combination. IL28B (rs8099917, rs12980275) genotyping was implemented using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method to detect its impact on HCV disease outcome. Results :Out of 150 patients, 141 (94%) were responders to treatment and 9 (6%) were non- responders. A total of 112 (74.7%) of patients belonged to mild to moderate stages of liver fibrosis and 38 (25.3%) had moderate to severe stages. There was a significant increase in severity of fibrosis among non-responders (p value <0.001*), where all of them had late fibrosis.GG genotype of IL28B (rs8099917) was concomitant with raised susceptibility to infection while TT genotype was predominant in controls, in responders and in patients with early fibrosis (p values>.0.05). while IL28B rs12980275 showed no significant difference among the study population. Conclusion: TT genotype of IL28B (rs8099917) may be a protective factor against infection and associated with probability of achieving sustained virologic response (SVR) to combined SOF and DCV therapy in genotype 4 HCV patients. However,GG genotype is negatively associated with HCV infection outcome. IL28B rs12980275 variants had no association with HCV infection. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
